Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
•
ASCO 2026
Assuming approval, in which patients would you choose Belzutifan + Lenvatinib (LITESPARK-011) for advanced RCC, with progression after IO therapy?
Related Questions
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
In a patient with de novo metastatic RCC s/p Ipi/Nivo with partial response and residual viable RCC on cytoreductive nephrectomy, would you add cabozantinib or other TKI prior to disease progression?
Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?
What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy?
For mCRPC patients who are eligible for both, how do you decide between Enzalutamide+Rad223 (EORTC 1333/PEACE-3) or Enzalutamide+Lu-PSMA-617 (ENZA-p)?
Will you extrapolate EORTC 1333/PEACE-3 (enzalutamide + Rad223) to any other ARPIs for mCRPC?
